Amprion Amprion

Amprion pioneers Prion Early Detection Testing℠ for Alzheimer’s and Parkinson’s. For the first time in history, our proprietary molecular-based diagnostic technology tracks the biomarkers, aka prions ... including Abeta, Tau and Synuclein, that drive Alzheimer’s and Parkinson’s prior to any clinical symptoms. Currently awarded FDA Breakthrough Device Designation for the detection of misfolded Synuclein, a biomarker for Parkinson’s, the company is also applying the same assay to detect misfolded Abeta and Tau, which are known to cause Alzheimer’s. Amprion expects to obtain FDA approvals in the next 18 months and to launch various early detection testing for Alzheimer’s and Parkinson’s accordingly. Early diagnosis of Alzheimer’s and Parkinson’s empowers us to find a cure to stop these diseases on their tracks. Learn more about ParkinZheimer—our philosophy and a pillar of our scientific discovery—Alzheimer’s and Parkinson’s are two related diseases on a spectrum: https://www.amprionme.com/our-philosophy/ Join us in the fight for brain health. Sign up for email alerts on our latest breakthroughs: https://www.amprionme.com/join-the-fight/ == About FDA Breakthrough Device Designation === FDA’s Breakthrough Devices Program is designed to speed up development, assessment and review of medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. == How Amprion Works === Amprion’s breakthrough early testing for Alzheimer's and Parkinson's tracks the prion biomarkers, using spinal fluid (CSF) and/or blood. Learn more at https://AmprionMe.com. Join the Fight For Brain Health #BrainHealth Read more

• Biotechnology